<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3330">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113501</url>
  </required_header>
  <id_info>
    <org_study_id>HighGradeT1 Bladder Cancer HVH</org_study_id>
    <nct_id>NCT02113501</nct_id>
  </id_info>
  <brief_title>Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study</brief_title>
  <official_title>Optimized Treatment Strategy for HighGradeT1 (HGT1) Bladder Cancer Based on Substaging (Depth of Lamina Propria Invasion): a Prospective Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>Spain: Departament de Salut de la Generalitat de Catalunya</authority>
    <authority>Spain: GCP (GCMP/ICH/135/95)</authority>
    <authority>Spain: Royal Decree 223/2004</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-muscle invasive bladder cancer of High Grade stage T1 (HGT1), has up to 20% risk of
      progression to invasive disease. Because the depth of substaging seems to identify two
      separate groups with different progression risk (HighGradeT1a and HighGradeT1b), we design a
      differential treatment strategy for each group. The main hypothesis is that HighGradeT1a
      bladder cancer can spare a second endoscopic procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only cases of initial diagnosis of HighGradeT1 and with a complete transurethral endoscopic
      resection (TUR) of bladder tumor) can enter this protocol. HighGradeT1a will only receive
      standard BCG treatment (induction and maintenance). HighGradeT1b will undergo a second
      transurethral endoscopic resection (TUR) after the induction of Bacillus de Calmette-Guerin
      (BCG) and then continue mantenaince BCG and standard follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>progression</measure>
    <time_frame>5year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>5year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>5year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>HGT1a</arm_group_label>
    <description>HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGT1b</arm_group_label>
    <description>HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      paraffin embedded blocks of transurethral resection (TUR) samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Initial HGT1 bladder cancer patients that have undergone a complete TUR and are willing to
        enter the protocol.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HGT1 bladder cancer at initial diagnosis and after a complete TUR

        Exclusion Criteria:

          -  abscence of muscularis propria in the TUR specimen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Orsola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron, Barcelona, Spain</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. BJU Int. 2010 Jan;105(2):202-7. doi: 10.1111/j.1464-410X.2009.08694.x. Epub 2009 Jun 24.</citation>
    <PMID>19558557</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HGT1</keyword>
  <keyword>high risk bladder cancer</keyword>
  <keyword>substaging</keyword>
  <keyword>repeat transurethral resection (reTUR)</keyword>
  <keyword>lamina propria</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
